The three leading Covid-19 vaccines are making their way towards the first line of beneficiaries. While the Pfizer and Moderna vaccines are being administered in tens of countries, the Oxford-AstraZeneca (Ox-As) jab was recently approved by India. All of them, to varying extent, have proven to be effective enough for usage. But the Ox-As vaccine fares the best in terms of commitment towards a more equitable distribution, chart 1 shows.
Most vaccines are not yet available in plenty, and are costly, too. So much so that rich countries have taken the lead in purchase deals, and reported